Recently, cardiac nitric oxide (NO) synthesis and endothelial NO synthase were shown to increase by LP, which was accompanied by a decrease in glucose uptake and use, and a corresponding increase in fatty acid uptake. 10, 11 The mechanism for
T he maternal adaptations of pregnancy are complex, coordinated, and dynamic. Fetal demands take precedence over maternal needs. In early pregnancy, maternal metabolism is largely anabolic to promote the accumulation of substrates to prepare for catabolic late pregnancy (LP), when fetal growth is at its highest. 1 The developing fetus uses glucose, lactate, fatty acids, and amino acids for energy provision and biosynthetic activities. Maternal metabolism submits to those needs by deferring its own glucose usage. Insulin sensitivity is profoundly affected, so much so that the insulin resistance of LP is comparable to that found in type 2 diabetes mellitus. 2 Consequent increased lipolysis in adipose tissue facilitates the use of lipids as the primary maternal energy source. Despite the insulin resistance, serum glucose levels drop, reflecting voracious consumption by the fetus. The mechanisms responsible for insulin resistance are unknown, although studies have shown that pregnancy hormones, such as TNF-α (tumor necrosis factor-α), can affect insulin sensitivity. 3 
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The maternal heart undergoes significant hemodynamic and structural changes during pregnancy. Cardiac output is augmented by 20% to 50% by LP as heart rate and stroke volume both increase. 4 All 4 cardiac chambers and all valves enlarge, in response to preload increase and volume overload of pregnancy. 5 Left ventricular mass increases by as much as 50%. These drastic alterations in cardiac morphology and function underscore the need for corresponding metabolic changes in the heart.
The metabolic adaptations of the heart during pregnancy are not well characterized. 6 Previous studies in rats showed that the heart reduces its glucose consumption, by as much as 75% by LP, and fulfilling its needs instead with fatty acids. [7] [8] [9] this substrate switch, however, has not been explored. It is often assumed that gestational insulin resistance affects the heart as it does other organs, but this has not been studied. In fact, if anything, phosphorylation of Akt is increased in LP, indicating that signaling through the insulin pathway is intact. [12] [13] [14] Hormones secreted during pregnancy have been postulated to play a role, but studies in the context of pregnancy have not been reported.
Here, we sought to understand how cardiac metabolism is affected in pregnancy by exploring cardiac substrate utilization and metabolic regulation during LP in mice, using 13 C-tracer analyses 15 and ex vivo Langendorff-perfused hearts.
Methods
Complete experimental procedures are given in the Online Data Supplement.
Animal Studies
All animal studies were performed according to procedures approved by the Institutional Animal Care and Use Committees at Beth Israel Deaconess Medical Center and the University of Pennsylvania. Female mice undergoing estrus were mated with C57/bl6 breeder males. The presence of a copulatory plug was denoted as day 0 of pregnancy.
Statistical Analysis
P values were calculated using the 2-tailed Student t test. For statistical comparisons between study groups, 2-way ANOVA was used. P <0.05 was considered as statistically significant. Data are displayed as mean±SD or SE (as indicated).
Results

Cardiac Fatty Acid Concentrations, Uptake, and Accumulation Increase in LP
Cardiac metabolic changes during pregnancy in mice have not been reported to date. We used an LP model in C57Bl/6 mice. Gestation typically lasts 19±0.5 days in this strain, 16 so we chose day 18 as representative of LP. Morphometric analysis showed that at day 18, a ≈13% increase in heart weight:tibia length ratios is observed ( Figure 1A) , consistent with what has been found in previous studies and indicative of physiological hypertrophy. Heart weight to body weight drops, reflecting gains in body weight during pregnancy. No significant change in plasma glucose was detected, whereas both triglyceride and free fatty acid concentrations were significantly higher in late gestation ( Figure 1B ), as seen in other species including humans, and consistent with the lipolytic environment of LP. We next quantified the extent of fatty acid uptake into the heart during LP. To do so, we used an assay recently described, in which a luciferin-conjugated long-chain free fatty acid (FFA) is delivered intravenously to mice that ubiquitously express the luciferase enzyme. 17 Uptake of luciferin-conjugated long-chain FFA into tissues exposes the tracer to the reduced intracellular environment, which liberates the luciferin moiety, leading to bioluminescence in the presence of luciferase ( Figure 1C ). Quantification of FFA uptake can therefore be achieved noninvasively by in vivo bioluminescence imaging. As shown in Figure 1D and 1E, LP mouse hearts take up 20% more fat than nonpregnant controls. These studies thus indicate that mice in late gestation increase the uptake and accumulation of cardiac fatty acids.
Substrate Switch in LP Mouse Hearts
The heart is generally omnivorous, consuming most substrates to which it is exposed. Does the increase in cardiac ([U- 13 C]palmitate) was then substituted for 30 minutes of perfusion, after which hearts were harvested for evaluation by mass spectrometry for incorporation of labeled isotopomer species into glycolytic and tricarboxylic acid (TCA) metabolites ( Figure 2A ). As shown in Figure 2B and 2C, hearts from late gestational mice incorporate 30% to 50% less glucose and lactate into TCA cycle intermediates than hearts from nonpregnant controls. In contrast, there is a 15% to 20% increase in relative flux of fatty acids into citrate, α-ketoglutarate, glutamate, succinate, and malate (aspartate and succinate were not significant; Figure 2D ). Thus, during LP, a substrate switch occurs in the heart that decreases glycolytic flux into the TCA cycle and increases fatty acids usage as an energy source. No changes were detected in anapleurotic glycolytic flux into the TCA via PC (pyruvate carboxylase)-mediated carboxylation of pyruvate to oxaloacetate, as determined by step increase in the M+3/M+2 ratio from succinate to aspartate, or comparison of M+3/M+2 ratio from glucose versus fatty acids (Online Figure IA and IB). Both nonpregnant and LP hearts were exposed to the same substrates but consumed them differently. Thus, differences in substrate utilization during pregnancy are because of adaptations that are intrinsic to the heart.
Insulin Signaling and Substrate Transporter Localization Are Unaltered
Maternal insulin resistance is a hallmark of pregnancy. Maternal tissues become less sensitive to insulin to promote fetal uptake of glucose. We tested whether abnormal insulin signaling is responsible for the change in substrate utilization. We found, however, that the ratio of phosphorylated Akt to total Akt was unaltered in LP hearts ( Figure 3A ; Online Figure  IIA ). In contrast, in skeletal muscle, a trend toward decreased Akt activity was observed in LP, suggesting insulin resistance in that tissue (Online Figure IIB) . Also, there was no significant change in the ratio of phospho-PI3K/PI3K (phosphoinositide 3-kinase) in the heart ( Figure 3A ; Online Figure IIA ). Addition of exogenous insulin led to robust induction of phosphorylated Akt in the heart, with no difference between nonpregnant and LP mice (Online Figure IIC) . In contrast, insulin-stimulated phosphorylation of Akt in the liver was blunted, consistent with the hepatic insulin resistance in LP. Thus, cardiac tissue does not seem to develop blunted insulin signaling in LP, in contrast to other tissues. Interestingly, phospho-mTOR/mTOR (mammalian target of rapamycin) was upregulated, consistent with the hypertrophic phenotype of late gestation ( Figure 3A ; Online Figure IIA) . Circulating insulin levels, as reported previously, 18, 19 were elevated in LP (Online Figure IID) . Insulin signaling increases glucose uptake via translocation of GLUT4 (glucose transporter type 4) and other transporters to the plasma membrane. We found no differences in the cardiac expression of glucose transporters Glut1 and Glut4, or of lactate and ketone body membrane carriers Mct1 (monocarboxylate transporter) and Mct4, during LP ( Figure 3B ). Mild induction of gene expression of the fatty acid translocase Cd36 (cluster of differentiation 36) was seen ( Figure 3B ), but no differences in protein levels of Glut4 and Cd36 were seen ( Figure 3C ; Online Figure IIE) . Importantly, there were also no alterations in the localizations of GLUT4 or CD36, as discerned by immunohistochemistry and subcellular fractionation ( Figure 3D ; Online Figure IIF ). Thus, it seems that the dramatic changes in substrate use seen in LP (Figure 2 ) cannot be explained by the suppression of insulin-mediated substrate transporter expression or localization, suggesting that mechanisms other than gestational resistance to insulin signaling are at play.
Late Gestation Does Not Affect Mitochondrial Content or Respiratory Capacity
We examined the ratio of mitochondrial DNA to genomic DNA and observed no changes in mitochondrial copy number ( Figure 3E ). Transmission electron microscopy revealed no discernable change in the quantity, density, or morphology of mitochondria in the heart during LP ( Figure 3F ). In accord with this, expression of electron transport chain subunits was also similar in hearts from LP mice, compared with controls ( Figure 3G) , and neither nuclear nor mitochondrial encoded genes were Figure IIIC) . To evaluate mitochondrial function directly, we used the Seahorse Extracellular Flux Analyzer to measure oxygen respiration in isolated mitochondria from hearts of LP mice, versus nulliparous controls. We observed no significant difference in respiratory capacity, regardless of the choice of substrate of pyruvate/ malate ( Figure 3H ) or palmitoylcarnitine/malate ( Figure 3I ), although we did note a trend for decreased consumption of pyruvate ( Figure 3H ). We conclude that the mitochondrial content, or respiratory capacity of mitochondria, in hearts from LP mice is not distinctively different from control mouse hearts and is thus unlikely to explain the observed strong changes in substrate use.
Progesterone Induces PDK4 (Pyruvate Dehydrogenase Kinase 4) Expression, Leading to PDH Phosphorylation in LP Hearts
PDKs (pyruvate dehydrogenase kinases) control the activity of PDH (pyruvate dehydrogenase) by inhibitory phosphorylation on multiple residues, thereby preventing entry of glycolytic products into the TCA cycle, in parallel leading to reciprocal increased fatty acid oxidation. While looking for insulinindependent changes that could explain the observed substrate switch in hearts in late gestation, we noted that Pdk4 is upregulated in LP specifically in striated muscle and more prominently in cardiac muscles than in skeletal muscles ( Figure 4A ; Online Figure IVA) . Conversely, Pdp1 and Pdp2 (PDH phosphatases 1 and 2), the prominent phosphatases that reverse the PDK-mediated phosphorylation of PDH, are downregulated in the heart and muscle in LP ( Figure 4A ; Online Figure IVA) . The induction of Pdk4 is exclusive to LP ( Figure 4B ). Protein expression of PDK4 mirrors the gene expression, with a 5-fold increase in late gestation (Online Figure IVB through IVD) . Consistent with increased activity of PDK4, phosphorylation of PDH at the 3 primary inhibitory serine sites (232, 293, and 300) was strikingly increased in LP ( Figure 4C ), and PDH activity was dramatically reduced (Online Figure IVE) .
By what mechanism is Pdk4 gene expression induced in LP? To investigate this question, isolated neonatal rat ventricular myocytes were treated with various pregnancy hormones. Whereas neither estrogen nor prolactin altered expression, progesterone increased Pdk4 expression >8-fold ( Figure 4D ). Progesterone is induced during pregnancy, both in mice and humans. 12 To test whether the progesterone receptor is required for this effect, we used a receptor partial agonist/ antagonist, mifepristone (RU486) to pretreat neonatal rat ventricular myocytes for 1 hour before progesterone incubation. Mifepristone treatment alone led to a modest increase in Pdk4 expression because of its partial agonist activity. The induction of Pdk4 by progesterone, however, was fully blocked in the presence of mifepristone, indicating that the induction is progesterone receptor mediated ( Figure 4E ). Data culled from chromatin immunoprecipitation sequencing (ChipSeq) experiments 20 demonstrated that the progesterone receptor binds directly to the Pdk4 promoter and a region ≈10 kb upstream, and receptor binding was markedly increased by the presence of progesterone (Online Figure IVF) . ENCODE data 21 demonstrates that both of these regions are hypersensitive to DNAseI digestion and contain a high amount of histone acetylation at H3K27, indicating high transcriptional regulatory activity at both sites. Both regulatory sites contain strong candidate progesterone-binding sequences 22 (Online Figure IVF) , consistent with the observed progesterone receptor binding. The 15 kb upstream region of Pdk4 also contains 3 single-nucleotide polymorphisms that act as expression quantitative trait loci for Pdk4 expression 23, 24 (Online Figure IVF) . Strikingly, 2 of these 3 expression quantitative trait loci are found within the 2 progesterone receptor-bound regions. Even more strikingly, the expression quantitative trait locus identified in the proximal region directly modifies the progesterone receptor binding site (Online Figure IVF) . These data thus unequivocally demonstrate that these sites regulate Pdk4 expression, with significant contribution from progesterone receptor binding in response to the presence of progesterone. In vivo, treatment of nulliparous mice, or even male mice, with 14 days of estrogen plus progesterone, thereby mimicking pregnancy, was sufficient to drive cardiac Pdk4 expression (Online Figure  IVG) . We conclude that progesterone drives the induction of cardiac Pdk4 during pregnancy. 
PDK4 Inhibition Reverses the Substrate Switch of LP
To assess whether the increase in PDK4 in LP is responsible for the decrease in glycolytic input into the TCA cycle, hearts were again perfused in the Langendorff mode in the presence of 13 C-labeled glucose, but this time treated with dichloroacetate (DCA), a well-established and widely used PDK inhibitor. 25 Treatment of hearts from LP mice with DCA led to a striking reversal of the inhibition of glucose oxidation, as manifested by recovered incorporation of 13 C label into all TCA intermediates ( Figure 4F ). Treatment of nulliparous mouse heart did not produce a significant effect. DCA had no effect on PDK4 expression (Online Figure VA) , consistent with its direct inhibition of PDK4 activity. DCA treatment also had no overt effect on cardiac contractile function, as measured by noninvasive echocardiography ( Figure 4G ; Online Figure VB) , indicating that the inhibition of PDH observed in LP is dispensable for normal contraction to occur. Interestingly, DCA treatment did reduce pregnancy-induced hypertrophy (Online Figure VC) , suggesting that metabolic reprogramming may have a direct effect on growth parameters, for example, by sparing glucose and lactate carbons for anabolic processes. We conclude that inhibition of PDH, most likely mediated by the induction of PDK4, is responsible for the substrate switch in cardiac fuel observed in LP.
Discussion
Maternal insulin resistance occurs normally during pregnancy to ensure sufficient fetal consumption of glucose. Changes in insulin signaling and sensitivity during pregnancy have been well characterized in skeletal muscle and other tissues, but not in cardiac muscle. 2 We show here that the insulin pathway, reflected in PI3K/Akt signaling and mTOR phosphorylation, is in fact not repressed in the heart during late gestation, and likely if anything is induced. Others have reported similar observations. [12] [13] [14] Insulin signaling and sensitivity thus do not decrease and instead may potentially increase in the heart during LP, unlike most other tissues in the body.
Despite insulin sensitivity, however, we find that cardiac glucose oxidation is decreased in late murine pregnancy. Previous studies demonstrated a similar substrate switch from glucose oxidation to increased fat import and consumption in rats and dogs. 7, 10 However, this was not previously characterized in mice, which is an important consideration as numerous genetic models of pregnancy-related cardiac diseases, such as in peripartum cardiomyopathy, are murine. Moreover, we provide here direct 13 C-tracer analyses to demonstrate entry into the TCA cycle, in actively beating hearts, of the respective nutrient sources. Mechanistically, we find that the substrate switch is inherent to the heart and does not merely reflect the dramatically altered availability of substrates during LP (eg, 4-fold increase in circulating free fatty acids, Figure 1B) . Instead, the substrate switch is caused in large part by the induction of PDK4, which leads to phosphorylation (and thus inhibition) of PDH. Conversely, expression of the phosphatases that reverse the inhibition of PDH (PDP1 and PDP2) is decreased in late gestation. Previous studies have reported conflicting results on the expression of PDK4, possibly reflecting species differences. Two groups found no change in PDH activity or PDK4 expression in day 18 pregnant rat hearts, whereas decreased PDH expression was observed in dogs. 8, 10, 26 In mouse hearts, a significant induction was found, consistent with our observations. 27 Thus, our data demonstrate not only clear induction of PDK4 but also that the induction is necessary for the substrate switch because inhibition of PDK with DCA reverses the energetic changes of pregnancy ( Figure 4F ).
Substrate switching away from glucose thus occurs in the heart as in other tissues, but not via reduced sensitivity to insulin signaling. Why use an alternate mechanism? There are at least 2 plausible explanations. First, perhaps it is important to maintain cardiac Akt and mTOR signaling in LP. Indeed, LP is a catabolic state for most maternal tissues (to supply nutrients to the fetus), but catabolism of cardiac muscle would likely be detrimental. Maintaining Akt and mTOR activity likely spares this outcome. Cardiac insulin resistance does occur in type 2 diabetes mellitus, leading to a substrate switch very similar to that of LP. But in type 2 diabetes mellitus, cardiac function declines, suggesting the need to maintain active insulin pathway signaling for cardiac health. Second, the heart in fact consumes lactate much more than glucose. Insulin resistance acts largely at the level of glucose entry into the cell and thus would not spare lactate consumption. Inhibition of PDH, on the other hand, blunts consumption of both substrates and thus spares lactate-derived gluconeogenic carbons for fetal use.
Our observations build on seminal work performed by Philip J. Randle and others, who showed that fatty acid oxidation can suppress glucose oxidation in part by suppressing pyruvate flux through PDH. [28] [29] [30] These classic studies demonstrated that inhibition of PDH occurs by allosteric productmediated inhibition and partly via enzyme phosphorylation. We show here that this process is also hormonally activated during pregnancy to preserve glucose and gluconeogenic substrates for the fetus. Progesterone, which peaks at the end of pregnancy, induces PDK4 expression directly in cardiomyocytes, as has been noted in rat skeletal muscle. 31 Other genomic and nongenomic effects of progesterone on cardiomyocytes have been reported previously, for example, induction of hypertrophy of isolated cardiomyocytes, 12 inhibition of cardiomyocyte apoptosis, 32 and modulation of cardiac repolarization. 33 But the effects of progesterone on cardiac metabolism have not been studied. 34 Progesterone is widely used clinically, usually in combination with estrogen, as hormone replacement therapy in perimenopausal women. We find that such a combination also induces PDK4 in cardiac cells both in cell culture and in vivo. It will thus be of interest to determine whether progesterone inhibits glucose oxidation in this context, what are the functional consequences, and whether coadministration of estrogen impacts the outcome, especially in light of the disappointing effects of hormone replacement therapy on cardiac health.
Our data also have interesting implications for pregnancy-related cardiac diseases. For example, peripartum cardiomyopathy, diagnosed by the onset of heart failure in late gestation or immediately postpartum, is a disease of unknown cause. 35, 36 One model for peripartum cardiomyopathy is the cardiac PGC-1α (PPARγ [peroxisome proliferator-activated receptor] coactivator-1α)-null mouse, which develops heart failure during LP and has vascular insufficiency and metabolic deficiency. 37 PGC-1α transcriptionally coactivates most nuclear receptors, regulates angiogenesis and mitochondrial biogenesis, and, in skeletal muscle, increases PDK4 expression during exercise or starvation. 38, 39 Disruption of appropriate regulation of PDK4 in LP may thus compromise the ability of the heart to switch substrate preferences appropriately. There may also be implications for the gestational disease of preeclampsia, in which cardiac dysfunction and clinical heart failure are often seen. 40 Preeclampsia is accompanied by large excesses of circulating vasoconstrictive and antivascular agents, which likely limit oxygen and nutrient supply to the heart and elsewhere. 41 Simultaneous inhibition of glucose oxidation by PDK4 may tip the balance to cardiac metabolic insufficiency. In other words, suppressing glucose oxidation to shunt glucose to the growing fetus may not be functionally maladaptive in a normal pregnancy (Figure 4 ), but it may become maladaptive in the context of additional stressors such as preeclampsia.
In conclusion, we use 13 C-tracer analyses to show that (1) LP promotes a metabolic switch in the heart, away from glucose oxidation and toward the use of fatty acids; (2) the choice of substrates reflects endogenous reprogramming in the heart, rather than exogenous fuel delivery; (3) the substrate switch occurs at the level of PDH, rather than at the level of insulin signaling or mitochondrial function; and (4) the process is driven by the hormonal environment of LP. These studies indicate that the LP hormonal milieu dictates the metabolic phenotype of the heart. A deeper understanding of these regulations could have significant impact on pregnancy-related cardiac diseases, such as peripartum cardiomyopathy or preeclamptic heart failure.
